Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|December 1, 2020
- Pharmaceutical Technology's In the Lab eNewsletter 12-02-2020
- Volume 15
- Issue 12
Nanoparticle Dissolution Testing Solution from Agilent Technologies
Author(s)Pharmaceutical Technology Editors
The system gives R&D formulation chemists the ability to manufacture new formulations sooner, while allowing manufacturing teams to supply reliable batches of new drug products for commercial sale in an automated and compliant manner.
Advertisement
The NanoDis System for nanoparticle dissolution testing from Agilent Technologies combines Agilent’s instrumentation and software to provide a system that is automatable and auditable.
The system gives R&D formulation chemists the ability to manufacture new formulations sooner, while allowing manufacturing teams to supply reliable batches of new drug products for commercial sale in an automated and compliant manner.
"Agilent's introduction of the NanoDis System is significant in that it is the first nanoparticle testing solution that allows methods to be easily transferred from R&D to QC, supporting scientists in meeting the requirements of United States Pharmacopeia," said Michael Frank, associate vice-president of global marketing for Agilent’s Liquid Phase Separation division, in a Nov. 23, 2020 company press release. "The NanoDis System can be universally implemented, therefore ensuring that our customers' global laboratory locations deliver the same results every time. Additionally, the NanoDis System is an end-to-end, single-vendor solution that is fully supported by a dedicated global team."
Source:
Articles in this issue
almost 6 years ago
Intricate Modalities Need More Perceptive Adventitious Agent Testingalmost 6 years ago
Foxx Life Sciences Opens New Headquarters in Indiaalmost 6 years ago
Certara to Open New Office in Chinaalmost 6 years ago
Bio-Rad StarBright Dyes for Flow Cytometry Offer Enhanced Resolutionalmost 6 years ago
Enzo’s New Portable Microplate Reader Simplifies Laboratory WorkflowAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement